| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.077 | 0.03 |
| mRNA | BRD-K51831558 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.03 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | -0.08 | 0.03 |
| mRNA | procarbazine | CTRPv2 | pan-cancer | AAC | -0.086 | 0.03 |
| mRNA | GDC-0941 | gCSI | pan-cancer | AAC | -0.13 | 0.03 |
| mRNA | DBeQ | CTRPv2 | pan-cancer | AAC | 0.079 | 0.03 |
| mRNA | XL765 | CTRPv2 | pan-cancer | AAC | 0.081 | 0.03 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | -0.068 | 0.03 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.08 | 0.03 |
| mRNA | selumetinib:navitoclax (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.076 | 0.04 |